Observational program to assess respiratory syncytial virus (RSV) hospitalization rate in population of children at high-risk of serious RSV illness who received palivizumab immunoprophylaxis (SUNRISE) - AbbVie
ClinicalTrials.gov. [Online] 2014. Accessed on November 13, 2021 at: